9.74 USD
↗ 0.17 (1.78%)AT CLOSE (11:59 AM EDT)
Corbus Pharmaceuticals Holdings, Inc.
CRBPNASDAQ • USD
9.72
↘ 0.03 (0.26%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
9.72
↘ 0.03 (0.26%)
Market: CLOSED
Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) are trading at $9.71. CRBP shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest CRBP is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Aug 6, 2026.
Open?$9.24
High?$9.84
Low?$9.18
Prev. Close?$9.57
Volume?158.0K
Avg. Volume?377.8K
VWAP?$9.64
Rel. Volume?0.42x
Bid / Ask
Bid?$8.71 × 100
Ask?$9.87 × 400
Spread?$1.16
Midpoint?$9.29
Valuation & Ratios
Market Cap?177.3M
Shares Out?18.5M
Float?15.9M
Float %?89.7%
P/E Ratio?N/A
P/B Ratio?1.40
EPS?-$4.56
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Themes
Employees
36
Market Cap
177.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-10-24
Address
500 RIVER RIDGE DRIVE
NORWOOD, MA 02062
Phone: 617-963-0103
NORWOOD, MA 02062
Phone: 617-963-0103
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?1
Momentum?23
Short Sent.?35
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.75Distress
Confidence?57%Low
Short InterestHigh
Short % of Float?13.18%High
Short Interest?2.1M
Days to Cover?5.9
Free Float15.9M
Avg Daily Volume355.5K
Settlement Date2026-07-15
Financial Health
Current Ratio?7.92Strong
Quick Ratio?7.92Strong
Cash Ratio?1.41Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.40CHEAP▾
Peers100
S&P89
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.7CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-66.9%WEAK▾
S&P3
ROA?-58.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-73654000
Enterprise Value?$151.6M
Fundamentals ratios updated end of day